Cue Biopharma Reports Positive Phase 2 CUE-221 Results
BOSTON — September 20, 2026 Cue Biopharma announced positive topline results from a Phase 2 study of CUE-221 (UB-221)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON — September 20, 2026 Cue Biopharma announced positive topline results from a Phase 2 study of CUE-221 (UB-221)...
BOSTON, Aug. 14, 2026 Cue Biopharma, Inc. reported continued progress across its clinical-stage pipeline, highlighted by the recent Investigational...
BOSTON, July 27, 2026 Bambusa Therapeutics announced encouraging preliminary proof-of-concept results from its ongoing global Phase 1 clinical trial...
HAMPTON, N.J., July 21, 2026 Celldex announced topline results from its Phase 2 clinical trial evaluating barzolvolimab in patients...
BASEL, Switzerland, June 8, 2026 Novartis announced the presentation of data from 10 scientific abstracts at the European Academy...
PISCATAWAY, N.J., June 4, 2026 Kashiv BioSciences has announced a significant regulatory milestone with the validation and acceptance by...
BRISBANE, Calif., May 14, 2026 Nurix Therapeutics presented new preclinical and Phase 1 translational data at the Society for...
Tarrytown, New York, USA & Paris, France – April 22, 2026 In a significant advancement for pediatric immunology and...
TARRYTOWN, N.Y. and PARIS, April 13, 2026 Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved...
Hyderabad, India, April 7, 2026 Phase 3 Trial Confirms Biosimilar Equivalence In a significant milestone for biosimilar drug development,...
